Literature DB >> 11477726

Prospective study of the patient-level cost of asthma care in children.

W J Ungar1, P C Coyte.   

Abstract

Our objective was to assess the cost of asthma care at the patient level in children from the perspectives of society, the Ontario Ministry of Health, and the patient. In this longitudinal evaluation, health service use data and costs were collected during telephone interviews at 1, 3, and 6 months with parents of 339 Ontario children with asthma. Direct costs were respiratory-related visits to healthcare providers, emergency rooms, hospital admissions, pulmonary function tests, prescription medications, devices, and out-of-pocket expenses. Indirect costs were parents' absences from work/usual activities and travel and waiting time. Hospital admissions accounted for 43%, medications for 31%, and parent productivity losses for 12% of total costs from a societal perspective. Statistically significant predictors of higher total costs were worse symptoms, younger age group, and season of participation. Adjusted annual societal costs per patient in 1995 Canadian dollars varied from $1,122 in children aged 4-14 years to $1,386 in children under 4 years of age. From the Ministry of Health perspective, adjusted annual costs per patient were $663 in children over 4 years and $904 in younger children. Adjusted annual costs from the patient perspective were $132 in children over 4 years and $129 in children under 4 years. The rising incidence of pediatric asthma demands that greater attention be paid to the delivery of optimal care to this segment of the population. Appropriate methods must be used to analyze healthcare costs and the use of services in the midst of widespread healthcare reform. The quality of clinical and health policy decision-making may be enhanced by cost-of-illness estimates that are comprehensive, precise, and expressed from multiple perspectives. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2001        PMID: 11477726

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  22 in total

1.  The hidden economic burden of air pollution-related morbidity: evidence from the Aphekom project.

Authors:  Olivier Chanel; Laura Perez; Nino Künzli; Sylvia Medina
Journal:  Eur J Health Econ       Date:  2015-12-09

Review 2.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

3.  Children in need of Pharmacare: medication funding requests at the Toronto Hospital for Sick Children.

Authors:  Wendy J Ungar; Carolyn Daniels; Ted McNeill; Mahdie Seyed
Journal:  Can J Public Health       Date:  2003 Mar-Apr

4.  Cost-effectiveness analysis of a system-based approach for managing neonatal jaundice and preventing kernicterus in Ontario.

Authors:  Bin Xie; Orlando da Silva; Greg Zaric
Journal:  Paediatr Child Health       Date:  2012-01       Impact factor: 2.253

5.  Better breathing or better living? A qualitative analysis of the impact of asthma medication acquisition on standard of living and quality of life in low-income families of children with asthma.

Authors:  Wendy J Ungar; Tony Macdonald; Martha Cousins
Journal:  J Pediatr Health Care       Date:  2005 Nov-Dec       Impact factor: 1.812

6.  Effect of Nebulized Magnesium vs Placebo Added to Albuterol on Hospitalization Among Children With Refractory Acute Asthma Treated in the Emergency Department: A Randomized Clinical Trial.

Authors:  Suzanne Schuh; Judy Sweeney; Maggie Rumantir; Allan L Coates; Andrew R Willan; Derek Stephens; Eshetu G Atenafu; Yaron Finkelstein; Graham Thompson; Roger Zemek; Amy C Plint; Jocelyn Gravel; Francine M Ducharme; David W Johnson; Karen Black; Sarah Curtis; Darcy Beer; Terry P Klassen; Darcy Nicksy; Stephen B Freedman
Journal:  JAMA       Date:  2020-11-24       Impact factor: 56.272

7.  Prescription pattern in asthma therapy at Gorakhpur hospitals.

Authors:  Awanish Pandey; Poonam Tripathi; Rishabh Dev Pandey
Journal:  Lung India       Date:  2010-01

8.  Socioeconomic factors and asthma control in children.

Authors:  Shannon F Cope; Wendy J Ungar; Richard H Glazier
Journal:  Pediatr Pulmonol       Date:  2008-08

Review 9.  Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma.

Authors:  Katherine A Lyseng-Williamson; Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 10.  Economic burden of asthma: a systematic review.

Authors:  Katayoun Bahadori; Mary M Doyle-Waters; Carlo Marra; Larry Lynd; Kadria Alasaly; John Swiston; J Mark FitzGerald
Journal:  BMC Pulm Med       Date:  2009-05-19       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.